Your browser doesn't support javascript.
loading
Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach.
Katsenou, Angeliki; O'Farrell, Roisin; Dowling, Paul; Heckman, Caroline A; O'Gorman, Peter; Bazou, Despina.
Affiliation
  • Katsenou A; Department of Electronics and Electrical Engineering, Trinity College Dublin, D02 PN40 Dublin, Ireland.
  • O'Farrell R; School of Computer Science, University of Bristol, Bristol BS1 8UB, UK.
  • Dowling P; Department of Electronics and Electrical Engineering, Trinity College Dublin, D02 PN40 Dublin, Ireland.
  • Heckman CA; Department of Biology, Maynooth University, W23 F2K8 Kildare, Ireland.
  • O'Gorman P; Institute for Molecular Medicine Finland-FIMM, HiLIFE-Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, 00290 Helsinki, Finland.
  • Bazou D; Department of Haematology, Mater Misericordiae University Hospital, D07 R2WY Dublin, Ireland.
Int J Mol Sci ; 24(21)2023 Oct 25.
Article in En | MEDLINE | ID: mdl-37958554
This paper describes a machine learning (ML) decision support system to provide a list of chemotherapeutics that individual multiple myeloma (MM) patients are sensitive/resistant to, based on their proteomic profile. The methodology used in this study involved understanding the parameter space and selecting the dominant features (proteomics data), identifying patterns of proteomic profiles and their association to the recommended treatments, and defining the decision support system of personalized treatment as a classification problem. During the data analysis, we compared several ML algorithms, such as linear regression, Random Forest, and support vector machines, to classify patients as sensitive/resistant to therapeutics. A further analysis examined data-balancing techniques that emerged due to the small cohort size. The results suggest that utilizing proteomics data is a promising approach for identifying effective treatment options for patients with MM (reaching on average an accuracy of 81%). Although this pilot study was limited by the small patient cohort (39 patients), which restricted the training and validation of the explored ML solutions to identify complex associations between proteins, it holds great promise for developing personalized anti-MM treatments using ML approaches.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proteomics / Multiple Myeloma Limits: Humans Language: En Journal: Int J Mol Sci Year: 2023 Document type: Article Affiliation country: Ireland Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proteomics / Multiple Myeloma Limits: Humans Language: En Journal: Int J Mol Sci Year: 2023 Document type: Article Affiliation country: Ireland Country of publication: Switzerland